Kisspeptin-10: what it is, what the studies show and where it stands
Kisspeptin-10 is the shortest kisspeptin fragment with full activity. Kisspeptins make the brain release GnRH, which raises LH and FSH.
At a glance
US Not approved
Canada Not authorized
Group Hormonal and sexual health
Sources 16
Checked 10 Oct 2026What is Kisspeptin-10?
Kisspeptin-10 is the shortest kisspeptin fragment with full activity. Kisspeptins make the brain release GnRH, which raises LH and FSH. Several human studies used the longer form, kisspeptin-54, the main form circulating in humans; rows below say which form was given. [1]
Other names: KP-10, Kp-10, kisspeptin 112-121, metastin 45-54.
How it has been given to people: intravenous bolus or infusion and subcutaneous bolus or pump infusion in research studies; kisspeptin-54 has also been given as a nasal spray.
Looking for doses? Kisspeptin-10 dosage chart and vial math
Is Kisspeptin-10 approved in the US and Canada?
United States: No FDA-approved kisspeptin product. Kisspeptin-10 is in Category 2 of FDA's 503A compounding list (substances that raise significant safety risks), added September 29, 2023 and still listed on the May 14, 2026 update. [13]
Canada: No kisspeptin product is in Health Canada's Drug Product Database. Health Canada has named kisspeptin and kisspeptin-10 among seized unauthorized injectable peptide drugs. [15]
Both were checked on 10 Oct 2026 against the regulators' own product databases.
Which approved products contain Kisspeptin-10?
No approved medicine containing Kisspeptin-10 was found in the US or Canada. Anything sold under this name is not a regulated product, so there is no label to check a dose against.
What human studies of Kisspeptin-10 exist?
The 13 findings listed here: 3 from randomized human trials and 10 from smaller or observational human studies.
Kisspeptin-54, not kisspeptin-10: in a crossover trial in 32 women with hypoactive sexual desire disorder, a 75-minute intravenous infusion changed brain responses to erotic videos and attractive faces. The main outcome was brain imaging, not a change in desire in daily life. [9]
Kisspeptin-54, not kisspeptin-10: in a crossover trial in 32 men with hypoactive sexual desire disorder, the same infusion changed brain responses to sexual videos and raised penile tumescence by up to 56% more than placebo. [10]
Kisspeptin-54, not kisspeptin-10: a nasal spray dose raised LH in healthy men, healthy women and women with hypothalamic amenorrhoea. [11]
Kisspeptin-10: in healthy men a single intravenous bolus raised LH within 30 minutes, more as the dose went up to 1 mcg/kg. [1]
Kisspeptin-10: a 22.5-hour intravenous infusion in 4 healthy men raised LH and testosterone. [1]
Kisspeptin-10: no effect on LH or FSH in healthy women in the follicular phase by any route tested, including subcutaneous injection. It did work in men and in women just before ovulation. [2]
Kisspeptin-10: after 5 days of continuous subcutaneous infusion in healthy men, testosterone was still raised but LH and FSH were no different from vehicle. [3]
Kisspeptin-10: 8-hour subcutaneous infusions each day kept LH raised through 12 days in healthy men. [3]
Kisspeptin-10: an 11-hour intravenous infusion raised LH and testosterone in 4 men with type 2 diabetes and low testosterone. The authors call it proof of concept. [4]
Kisspeptin-10: a 12-hour intravenous infusion raised LH, FSH and estradiol in 2 women whose periods had stopped because of high prolactin. [5]
Kisspeptin-54, not kisspeptin-10: plasma half-life was 27.6 minutes in 6 men after a 90-minute intravenous infusion. [6]
Kisspeptin-54, not kisspeptin-10: twice-daily injections in women with hypothalamic amenorrhea raised LH strongly on day 1 but the response had largely gone by day 14. [7]
Kisspeptin-54, not kisspeptin-10: a single subcutaneous injection triggered egg maturation in women having IVF; the clinical pregnancy rate was 23% (12 of 53). [8]
What are the side effects of Kisspeptin-10?
Reported in human studies or on a label:
- Kisspeptin-10: in the 12-hour infusion study in 2 women, no side effects were seen. This is a very small, short study. [5]
- Kisspeptin-54: no adverse effects were reported after a single 75-minute infusion in the trial in women with low sexual desire. [9]
- Kisspeptin-54 nasal spray: no side effects or adverse events in the single-dose study. [11]
- FDA says it has little or no safety information for compounded kisspeptin-10 by the proposed routes and cannot tell whether it would cause harm. [13]
- FDA also names a risk of immune reactions and of peptide impurities in compounded kisspeptin-10. [13]
How does Kisspeptin-10 compare with others in its group?
These are the peptides filed under hormonal and sexual health. The last column says whether a randomized human trial is on record for each.
| Peptide | US | Canada | Half-life | Randomized human trial |
|---|---|---|---|---|
| PT-141 (bremelanotide) | Approved for one use | Not authorized | About 2.7 hours after a single subcutaneous dose (the label gives a range of 1.9 to 4.0 hours). Blood levels peak at about 1 hour. | Yes |
| Kisspeptin-10 | Not approved | Not authorized | Not found | Yes |
| Gonadorelin | No longer sold | No longer sold | Very short. After intravenous or subcutaneous injection, blood levels fall with an initial half-life of 2 to 10 minutes and a terminal half-life of 10 to 40 minutes. | No |
| Testagen | Not approved | Not authorized | Not found | No |
| HCG | Approved, prescription | Authorized, prescription | About 32 to 33 hours after a single injection of 5,000 or 10,000 IU in 18 healthy women, the same by muscle or under the skin. | Yes |
| HMG | Approved, prescription | Authorized, prescription | FSH from Menopur had an elimination half-life of 11 to 13 hours after repeated doses, by injection under the skin or into a muscle. The label gives no half-life for the LH part. | Yes |
What could not be found
These were searched for and did not turn up. They are listed so a missing number is not mistaken for a hidden one.
- Human half-life of kisspeptin-10: not stated in any abstract or full text opened. The 27.6-minute figure in the literature is for kisspeptin-54 [6].
- No approved product or label, so no official dose, contraindications, interaction list or storage instructions.
- No human study of kisspeptin-10 given as a once-daily or few-times-a-week subcutaneous injection over weeks was found. The only repeated subcutaneous kisspeptin-10 data are pump infusions over 5 and 12 days in healthy men [3].
- No trial of kisspeptin-10 for low sexual desire was found. The two sexual-desire trials gave kisspeptin-54 by intravenous infusion [9], [10].
- No kisspeptin-10 study longer than 12 days was found, so there is no long-term safety record.
Kisspeptin-10 questions
Is Kisspeptin-10 approved in the US?
No FDA-approved kisspeptin product. Kisspeptin-10 is in Category 2 of FDA's 503A compounding list (substances that raise significant safety risks), added September 29, 2023 and still listed on the May 14, 2026 update.
Is Kisspeptin-10 authorized in Canada?
No kisspeptin product is in Health Canada's Drug Product Database. Health Canada has named kisspeptin and kisspeptin-10 among seized unauthorized injectable peptide drugs.
Has Kisspeptin-10 been tested in a randomized human trial?
Yes. At least one randomized human trial is listed on this page.
Sources
Each one was opened on 10 Oct 2026 and matched to the line it supports.
- George JT et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab 2011. PubMed 21632807.
- Jayasena CN et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab 2011. PubMed 21976724.
- Yeung AC et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol 2026. PubMed 42549827.
- George JT et al. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol (Oxf) 2013. PubMed 23153270.
- Millar RP et al. Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. J Endocr Soc 2017. PubMed 29264460.
- Dhillo WS et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab 2005. PubMed 16174713.
- Jayasena CN et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab 2009. PubMed 19820030.
- Jayasena CN et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest 2014. PubMed 25036713. Trial NCT01667406.
- Thurston L et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open 2022. PubMed 36287566.
- Mills EG et al. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open 2023. PubMed 36735255.
- Mills EG et al. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine 2025. PubMed 40215751.
- World Anti-Doping Agency World Anti-Doping Code International Standard Prohibited List 2026 2026. wada-ama.org.
- US Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026. fda.gov.
- US Food and Drug Administration Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act 2026. fda.gov.
- Health Canada Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks 2025. recalls-rappels.canada.ca.
- Health Canada Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks 2025. recalls-rappels.canada.ca.
Next
Kisspeptin-10 dosage5 mg vialHormonal and sexual healthStatus in Canada
DosageFacts is an information site. It is not medical advice. Talk to a licensed professional before using any medication.